Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

NCT02520245 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT02520245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02520245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 1
Overall status
Withdrawn
Start date
August 31, 2015
Completion date
November 30, 2023
Enrollment
0 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies